Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial

BACKGROUND: The 52-week monotherapy with the dipeptidyl peptidase-4 inhibitor sitagliptin and the sulphonylurea glimepiride on early-phase insulin secretion in Japanese patients with type 2 diabetes mellitus (T2DM) is not known. METHODS: A randomized, parallel-group, open-label trial was conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Yaeko, Harada, Norio, Hamasaki, Akihiro, Kaneko, Shizuka, Yasuda, Koichiro, Ogawa, Eiichi, Harashima, Shin-ichi, Yoneda, Hiroko, Fujita, Yoshihito, Kitano, Norikazu, Nakamura, Yoshio, Matsuo, Fujio, Shinji, Megumi, Hinotsu, Shiro, Nakayama, Takeo, Inagaki, Nobuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769515/
https://www.ncbi.nlm.nih.gov/pubmed/26925169
http://dx.doi.org/10.1186/s13098-016-0131-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769515/
https://www.ncbi.nlm.nih.gov/pubmed/26925169
http://dx.doi.org/10.1186/s13098-016-0131-y

Ejemplares similares